Current Landscape in Management of CLL and Updates on Preventative Approaches to Manage Risk of Covid-19 in Patients

At the end of the session participants will be able to:
-Identify the best evidence for clinical management of CLL and the impact of COVID-19 in treatment decision-making
-Evaluate current therapeutic options for COVID-19 in immunocompromised patients
-Identify COVID-19 preventative modalities other than vaccines for immunocompromised patients

Speaker:
Dr. Carolyn Owen, Associate Professor, Division of Hematology & Hematological Malignancies, University of Calgary. Hematologist, Tom Baker Cancer Centre, Calgary, Alberta

Target Audience: Hematologists

CanMEDS: Medical Expert (the integrating role), Health Advocate

Declaration of Conflict of Interest: AstraZeneca and AbbVie, honoraria for advising and speaking. Janssen-funded grant/clinical trial honoaria. Roche-patent on drug, product or device - honoraria. Beigene-honararia.

Accreditation: This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by the Canadian Association of Pathologists (CAP-AC). You may claim a maximum of 1.0 hours.

This webinar was co-developed with Astra Zeneca and the CHS and was planned to achieve scientific integrity, objectivity and balance.

00:54:00